Aeglea BioTherapeutics to Participate in September Investment Conferences
September 02, 2020 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics to Present at World Orphan Drug Congress USA 2020
August 18, 2020 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, Aug. 18, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics Reports Second Quarter 2020 Financial Results and Corporate Highlights
August 10, 2020 08:30 ET
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Showed Durable Clinical Response and Sustained Reduction in Plasma Arginine at 56 Week Analysis of Phase 1/2 Open-Label Extension Study Initiated Phase 1/2 Clinical Trial of ACN00177...
Aeglea BioTherapeutics to Present at BIO Digital 2020
June 01, 2020 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, June 01, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics Announces Change of Location of Annual Meeting of Stockholders to Be Held June 8, 2020
May 28, 2020 16:10 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Tx., May 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics Announces 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 26, 2020 08:30 ET
|
Aeglea BioTherapeutics, Inc.
Pegzilarginase Showed Durable Clinical Response at 56 Week Analysis All Patients Demonstrated a Marked and Sustained Reduction in Plasma Arginine Favorable Safety Profile, Consistent with...
Aeglea BioTherapeutics to Present Late-Breaking 1-Year Data for Pegzilarginase in Patients with Arginase 1 Deficiency at the 6th Congress of the European Academy of Neurology
May 19, 2020 08:30 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, May 19, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company developing a new generation of human enzyme therapeutics as...
Aeglea BioTherapeutics Reports First Quarter 2020 Financial Results and Corporate Highlights
May 07, 2020 08:30 ET
|
Aeglea BioTherapeutics, Inc.
Gross Proceeds of $138 Million from April 2020 Public Offering Extends Cash Runway Through 2022 Clinical Trial Application for ACN00177 Approved by MHRA; Progress Toward Phase 1/2 Clinical Trial in...
Aeglea BioTherapeutics Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
April 30, 2020 16:05 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 30, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as solutions...
Aeglea BioTherapeutics Announces Pricing of $120 Million Public Offering
April 28, 2020 09:07 ET
|
Aeglea BioTherapeutics, Inc.
AUSTIN, Texas, April 28, 2020 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (Nasdaq:AGLE), a clinical-stage biotechnology company developing next-generation human enzyme therapeutics as...